Fiche publication
Date publication
septembre 2020
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr LIMAGNE Emeric
,
Dr FUMET Jean-David
,
Dr THIBAUDIN Marion
Tous les auteurs :
Fumet JD, Limagne E, Thibaudin M, Ghiringhelli F
Lien Pubmed
Résumé
Chemotherapy is initially used to kill proliferative cells. In the current area of emerging immunotherapy, chemotherapies have shown their ability to modulate the tumor micro environment and immune response. We focus here on two main effects: first, immunogenic cell death, defined as a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response in immunocompetent hosts; and second, the depletion of suppressive cells, known to play a major role in immune escape and resistance to immunotherapy. In this review, we present a review of different classically used chemotherapies focusing on this double effect on immunity. These immunological effects of chemotherapy could be exploited to promote efficacy of immunotherapy. Broadening our understanding will make it possible to provide rationales for the combination of chemoimmunotherapy in early clinical trials.
Mots clés
cancer, chemotherapy, immunogenic cell death, immunosuppression, immunotherapy
Référence
Cancers (Basel). 2020 Sep 16;12(9):
